Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Rebamipide may help regrow hair by activating hair follicle stem cells.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Retinoic acid can either maintain stem cells or make them specialize, depending on the cell type.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

QLT0267 stops hair follicle cell growth and movement.

The oncoprotein causes abnormal hair growth without increasing skin cancer risk.

RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Estrogen Receptor ß (ERß) is the main hormone controller in human skin and hair follicles, not Estrogen Receptor α (ERα) or the Androgen Receptor (AR).

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Terminalia bellirica extracts effectively promote hair regrowth and treat androgenetic alopecia.

Antisense oligonucleotides can reduce androgen receptor levels in skin cells, suggesting potential for treating skin disorders.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

NDRG1 protein helps infantile hemangioma, a common infant tumor, to grow, and its mismanagement by FOXO1 protein plays a big role in causing the tumor.

Fibroblasts from healthy donors can prevent changes seen in recessive epidermolysis bullosa simplex.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.

Erlotinib can cause hair loss as a side effect.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

AKR1B10 enzyme may cause keloid scars and could be a treatment target.